文献速递银屑病与炎症性皮肤病

司库奇尤单抗在新发中重度斑块状银屑病患者中优于窄谱中波紫外线光疗:STEPIn 研究第 52 周结果

Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-27

STEPIn 研究为随机、开放标签、多中心研究,纳入新发(≤12 个月)中重度斑块状银屑病患者,比较司库奇尤单抗 300 mg 皮下注射 52 周与窄谱中波紫外线光疗。第 52 周司库奇尤单抗组 PASI 90 应答率 91.1%(70/77),窄谱中波紫外线组 42.3%(32/76),p<0.0001,OR 估计值 16.3(95%CI 5.6–46.9);IGA 0/1 应答率分别为 85.7% 与 36.8%(p<0.0001)。安全性特征与两治疗已知安全性一致,未出现新的或非预期安全信号。

要点

  • 新发中重度斑块状银屑病患者第 52 周 PASI 90:司库奇尤单抗组 91.1% vs 窄谱中波紫外线组 42.3%(p<0.0001)。
  • 第 52 周 IGA 0/1 应答率:司库奇尤单抗组 85.7% vs 窄谱中波紫外线组 36.8%(p<0.0001)。
  • 安全性数据与司库奇尤单抗和窄谱中波紫外线已知安全性特征一致,无新的或非预期安全信号。

核心结论

  • 司库奇尤单抗治疗新发中重度斑块状银屑病优于窄谱中波紫外线光疗。
  • 观察到的高且持续的皮损清除提示,银屑病生物制剂治疗若在疾病早期使用可能更有效。

研究设计与样本

  • STEPIn 研究为随机、开放标签、多中心研究(NCT03020199),比较司库奇尤单抗 300 mg 皮下注射 52 周与窄谱中波紫外线光疗标准治疗。
  • 纳入新发(≤12 个月)中重度斑块状银屑病患者;司库奇尤单抗组 80 例中 77 例、窄谱中波紫外线组 80 例中 76 例随机患者至少接受一剂研究治疗。

主要发现

  • 第 52 周 PASI 90 应答率:司库奇尤单抗组 91.1%(70/77)vs 窄谱中波紫外线组 42.3%(32/76),p<0.0001,OR 估计值 16.3(95%CI 5.6–46.9)。
  • 第 52 周 IGA 0/1 应答率:司库奇尤单抗组 85.7% vs 窄谱中波紫外线组 36.8%(p<0.0001)。
  • 安全性数据与司库奇尤单抗和窄谱中波紫外线的安全性特征一致,无新的或非预期安全信号。

关键数值与推荐

  • 主要终点为第 52 周 PASI 90 应答,司库奇尤单抗组 91.1%(70/77)vs 窄谱中波紫外线组 42.3%(32/76),p<0.0001,OR 估计值 16.3(95%CI 5.6–46.9)。
  • 附加次要终点为第 52 周 IGA(mod 2011)0/1 应答,司库奇尤单抗组 85.7% vs 窄谱中波紫外线组 36.8%(p<0.0001)。

临床怎么用

  • 作者认为,观察到的高且持续的皮损清除表明银屑病生物制剂治疗若在疾病早期使用可能更有效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic treatments have been studied mainly in patients with a long-term history of psoriasis and previous treatment failures. OBJECTIVES: The purpose of this primary analysis of the STEPIn study is to determine whether early intervention with secukinumab in patients with new-onset moderate to severe plaque psoriasis is superior to standard of care treatment with narrow band ultraviolet B (nb-UVB) phototherapy. METHODS: The STEPIn study is a randomized, open-label, multicentre study to investigate early intervention with 52 weeks of secukinumab 300 mg administered subcutaneously versus standard treatment with nb-UVB phototherapy in patients with new-onset (≤12 months) moderate to severe plaque psoriasis (NCT03020199). The primary and additional secondary endpoints were ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at Week 52 and Investigator's Global Assessment (IGA mod 2011) 0/1 response at Week 52, respectively. RESULTS: In the secukinumab and nb-UVB study arms, 77/80 and 76/80 randomized patients received at least one dose of study treatment, respectively. The primary endpoint was achieved: 91.1% (70/77) of patients achieved a PASI 90 response at Week 52 in the secukinumab arm versus 42.3% (32/76) in the nb-UVB arm (p < 0.0001, odds ratio [OR] estimate [95% confidence intervals, CI] = 16.3 [5.6, 46.9]). The additional secondary endpoint was also achieved: 85.7% of patients achieved an IGA 0/1 response at Week 52 in the secukinumab arm versus 36.8% in the nb-UVB arm (p < 0.0001). The safety data were consistent with the safety profiles of secukinumab and nb-UVB with no new or unexpected safety signals. CONCLUSIONS: Secukinumab was superior to nb-UVB in treating patients with new-onset moderate to severe plaque psoriasis. The high and sustained skin clearance observed indicates that biologic treatment for psoriasis may be more effective if used early in the disease course.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023. PMID: 36606536. doi:10.1111/jdv.18846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。